Syndax(US:SNDX) Globenewswire·2026-01-12 12:00Core Insights - Syndax Pharmaceuticals reported preliminary, unaudited financial results for Q4 2025 and full year 2025, highlighting significant revenue growth for its products Revuforj and Niktimvo, driven by increased demand following FDA approvals [1][2][5] Financial Performance - Revuforj generated approximately $44 million in Q4 2025 and $125 million for the full year 2025, with a 38% increase in Q4 revenue compared to Q3 2025 [1][5] - Niktimvo reported approximately $56 million in Q4 2025 and $152 million for the full year 2025, with Syndax expecting to report its 50% share of net commercial profit in the full year results [1][4][6] - The company ended 2025 with approximately $394 million in cash, cash equivalents, and marketable securities, indicating a fully funded position through profitability [1][13] Business Developments - The company secured its third FDA approval in 2025 and successfully launched Revuforj and Niktimvo, positioning itself for continued growth [2] - Revuforj received the 'Best New Drug' award at the Scrip Awards 2025, recognizing its therapeutic advancements [5] - Syndax initiated the REVEAL-ND Phase 3 trial for revumenib in newly diagnosed patients with NPM1m AML, aiming for accelerated approval [5][12] Future Outlook - The company plans to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, to discuss its business updates and future strategies [1][10] - Key priorities for 2026 include driving revenue growth for Revuforj and Niktimvo, completing clinical trials, and advancing pipeline development [13][14]